Althorugh kinase inhibitors have become the preferable anti-tumor target for pharmaceutical synthesis [44], the two main kinases involved in the Wnt/β-catenin pathway, namely CK1a and GSK3β, negatively modulate signaling and cannot serve as therapeutic targets for anti-tumor treatment. This evidence concerns the gene CSNK1A1 and neoplasm.